Lonza to add ADC capacity

Lonza will expand manufacturing capacity for antibody drug conjugates at its Visp, Switzerland, site. The company will invest CHF14m in facilities that are designed to handle both biological species and highly potent cytotoxic small molecule drugs. Lonza said the new capacity is expected to be complete in Q2 2014.
In-pharma Technologist